In particular, AML-patient MSCs significantly impair the expansion of human umbilical cord blood CD34+ progenitors and limit their differentiation to maintain a stable pool of immature quiescent precursors (CD34+ CD38−) compared to healthy donor-derived MSCs (hereafter healthy MSCs) [50]. The gene discussed is CD34; the disease is acute myeloid leukemia.